Literature DB >> 7596372

An atypical variant of Fabry's disease in men with left ventricular hypertrophy.

S Nakao1, T Takenaka, M Maeda, C Kodama, A Tanaka, M Tahara, A Yoshida, M Kuriyama, H Hayashibe, H Sakuraba.   

Abstract

BACKGROUND: Fabry's disease is considered very rare. Left ventricular hypertrophy is one of the common manifestations in adults with classic hemizygous disease. Recently, several cases of an atypical variant of hemizygous Fabry's disease, with manifestations limited to the heart, have been reported. Therefore, we assessed the incidence of hemizygosity for Fabry's disease among male patients with left ventricular hypertrophy.
METHODS: We measured plasma alpha-galactosidase activity in 230 consecutive male patients with left ventricular hypertrophy. Clinical manifestations were assessed, endomyocardial biopsies were performed, and the patients were screened for mutations in the alpha-galactosidase gene.
RESULTS: Seven of the 230 patients with left ventricular hypertrophy (3 percent) had low plasma alpha-galactosidase activity (0.4 to 1.2 nmol per hour per milliliter; 4 to 14 percent of the mean value in normal controls). These seven unrelated patients, ranging in age from 55 to 72 years, did not have angiokeratoma, acroparesthesias, hypohidrosis, or corneal opacities, which are typical manifestations of Fabry's disease. Endomyocardial biopsy was performed in five patients and revealed marked sarcoplasmic vacuolization in all five. Samples from four patients were examined by electron microscopy and revealed typical lysosomal inclusions with a concentric lamellar configuration in all four. Two patients had novel missense mutations in exon 1 (Ala20Pro) and exon 6 (Met296lle). The remaining five had no mutations in the coding region of the alpha-galactosidase gene, but the amounts of the alpha-galactosidase messenger RNA were markedly lower than normal.
CONCLUSIONS: Seven unrelated patients with atypical variants of hemizygous Fabry's disease were found among 230 men with left ventricular hypertrophy (3 percent). Fabry's disease should be considered as a cause of unexplained left ventricular hypertrophy.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7596372     DOI: 10.1056/NEJM199508033330504

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  165 in total

1.  Alpha-galactosidase A-Tat fusion enhances storage reduction in hearts and kidneys of Fabry mice.

Authors:  Koji Higuchi; Makoto Yoshimitsu; Xin Fan; Xiaoxin Guo; Vanessa I Rasaiah; Jennifer Yen; Chuwa Tei; Toshihiro Takenaka; Jeffrey A Medin
Journal:  Mol Med       Date:  2010-02-17       Impact factor: 6.354

2.  Fabry disease in genetic counseling practice: recommendations of the National Society of Genetic Counselors.

Authors:  Robin L Bennett; Kimberly A Hart; Erin O'Rourke; John A Barranger; Jack Johnson; Kay D MacDermot; Gregory M Pastores; Robert D Steiner; Ravi Thadhani
Journal:  J Genet Couns       Date:  2002-04       Impact factor: 2.537

3.  Fabry disease: a mimic for obstructive hypertrophic cardiomyopathy?

Authors:  S R Ommen; R A Nishimura; W D Edwards
Journal:  Heart       Date:  2003-08       Impact factor: 5.994

4.  Fabry disease.

Authors:  S F Nagueh
Journal:  Heart       Date:  2003-08       Impact factor: 5.994

Review 5.  Nuclear cardiac imaging in hypertrophic cardiomyopathy.

Authors:  Jamshid Shirani; Vasken Dilsizian
Journal:  J Nucl Cardiol       Date:  2011-02       Impact factor: 5.952

Review 6.  Hypertrophic cardiomyopathy.

Authors:  Carolyn Y Ho
Journal:  Heart Fail Clin       Date:  2010-04       Impact factor: 3.179

Review 7.  Utility of late gadolinium enhancement in pediatric cardiac MRI.

Authors:  Maryam Etesami; Robert C Gilkeson; Prabhakar Rajiah
Journal:  Pediatr Radiol       Date:  2015-12-30

8.  Improvement in the sensitivity of newborn screening for Fabry disease among females through the use of a high-throughput and cost-effective method, DNA mass spectrometry.

Authors:  Yung-Hsiu Lu; Po-Hsun Huang; Li-Yun Wang; Ting-Rong Hsu; Hsing-Yuan Li; Pi-Chang Lee; Yu-Ping Hsieh; Sheng-Che Hung; Yu-Chen Wang; Sheng-Kai Chang; Ya-Ting Lee; Ping-Hsun Ho; Hui-Chen Ho; Dau-Ming Niu
Journal:  J Hum Genet       Date:  2017-11-15       Impact factor: 3.172

9.  Frequency of unrecognized Fabry disease among young European-American and African-American men with first ischemic stroke.

Authors:  Marcella A Wozniak; Steven J Kittner; Stanley Tuhrim; John W Cole; Barney Stern; Mark Dobbins; Marie E Grace; Irina Nazarenko; Robert Dobrovolny; Eric McDade; Robert J Desnick
Journal:  Stroke       Date:  2009-12-10       Impact factor: 7.914

10.  The Fabry disease-causing mutation, GLA IVS4+919G>A, originated in Mainland China more than 800 years ago.

Authors:  Kung-Hao Liang; Yung-Hsiu Lu; Chih-Wei Niu; Sheng-Kai Chang; Yun-Ru Chen; Chih-Ya Cheng; Ting-Rong Hsu; Chia-Feng Yang; Kimitoshi Nakamura; Dau-Ming Niu
Journal:  J Hum Genet       Date:  2020-04-03       Impact factor: 3.172

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.